Moderna swings to profit as cancer-vaccine momentum gathers pace
Moderna swung to a profit as momentum builds around its cancer-vaccine programme, according to the Financial Times. The result gives investors a fresh test of whether pipeline progress can offset the company’s still-declining revenue base.
STOCK PHOTO · JAKUB ZERDZICKIThe story
Moderna has swung to profit as momentum builds around its cancer-vaccine programme, the Financial Times reported on November 6. The report also identified the biotech as the strongest performer in the S&P 500 over the past year.
The development marks a change from Moderna’s latest full-year company figures, which showed 2025 revenue of $1.9 billion, down 39.9% year on year, alongside a net loss margin of 145.2% and diluted EPS of $-7.26. The current profit report therefore sits against a recent period of sharply lower sales and substantial losses.
The names directly connected to the story are Moderna and its cancer-vaccine programme: the mechanism is that progress in the programme is helping support investor momentum around the company’s pipeline, while the reported profit provides a counterpoint to the decline in the established revenue base.
The scale and composition of the reported profit, as well as the specific clinical or commercial milestones behind the cancer-vaccine momentum, remain unclear. The company’s latest annual figures also do not establish whether the reported improvement is recurring or driven by a one-off item.
The next evidence will be Moderna’s next financial update and any dated clinical or regulatory milestones for the cancer-vaccine programme. Investors will need the profit’s size, its cash and revenue drivers, and further pipeline progress to assess whether the change is durable.
Our read · Fri, Nov 6
Moderna (MRNA) swung to profit as momentum builds around its cancer-vaccine programme.
Why. The immediate consequence is a sharper test of whether pipeline momentum can replace a shrinking commercial base: Moderna’s 2025 revenue was $1.9 billion, down 39.9% year on year, while net margin was -145.2% and diluted EPS was $-7.26. The reported profit is encouraging, but without its size and composition there is no dated catalyst to support a directional read beyond the next results update.
Both cases
What could change this view: The read fails if the profit proves non-recurring or if cancer-vaccine progress does not translate into clinical, regulatory or commercial milestones.
Who reported it · 1
Keep reading
More on MRNA
Moderna cancer vaccine cuts melanoma recurrence or death by 42%Moderna (MRNA), Merck (MRK) Cancer Vaccine Wins in Late-Stage TrialModerna shares surge 179% on melanoma therapy; revenue fell 39.9% to $1.9BModerna revenue fell 39.9% to $1.9B in FY with -145.2% net marginLatest on the Wire
SMCI files 10-Q — Quarterly Report: 10-QHims ends GLP-1 compounding in Lilly deal as shares rallyUS adds 165,000 jobs in October as wages rise and unemployment fallsTrump weighs renewed Iran strikes as negotiators review a new proposalTesla to wind down Cybertruck production as Musk pivots to roboticsContinue on the Wire →Latest on the Wire
Tesla to wind down Cybertruck production as Musk pivots to roboticsFormer BOJ economist sees December hike and 2% terminal rateUS job growth expected to pick up in October, with moderation in wage gainsRepublican lawmakers seek Jensen Huang briefing after China spying reportsContinue on the Wire →Top this week
Democrats sweep Congress, setting Trump up for legislative gridlockFutures rebound after blue sweep as dollar slides and gold tops $4,000Bitcoin plunges as AI chip selling drags Nasdaq down more than 2%Trump’s Republican Party faces a midterm verdict from US voters todayBitcoin faces renewed pressure as Binance hack intensifies market fearAbout this report
Reported by Financial Times as Moderna swings to profit as momentum for cancer vaccine builds
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →